Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study.
Sakai D, Omori T, Fumita S, Fujita J, Kawabata R, Matsuyama J, Yasui H, Hirao M, Kawase T, Kishi K, Taniguchi Y, Miyazaki Y, Kawada J, Satake H, Miura T, Miyake A, Kurokawa Y, Yamasaki M, Yamada T, Satoh T, Eguchi H, Doki Y. Sakai D, et al. Among authors: satake h. Int J Clin Oncol. 2022 Jul;27(7):1154-1163. doi: 10.1007/s10147-022-02162-4. Epub 2022 Apr 30. Int J Clin Oncol. 2022. PMID: 35489010 Free PMC article.
Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).
Satake H, Iwatsuki M, Uenosono Y, Shiraishi T, Tanioka H, Saeki H, Sugimachi K, Kitagawa D, Shimokawa M, Oki E, Emi Y, Kakeji Y, Tsuji A, Akagi Y, Natsugoe S, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer. Satake H, et al. Cancer Chemother Pharmacol. 2017 Jan;79(1):147-153. doi: 10.1007/s00280-016-3204-6. Epub 2016 Dec 10. Cancer Chemother Pharmacol. 2017. PMID: 27942930 Free PMC article. Clinical Trial.
A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).
Ando K, Emi Y, Suenaga T, Hamanoue M, Maekawa S, Sakamoto Y, Kai S, Satake H, Shimose T, Shimokawa M, Saeki H, Oki E, Sakai K, Akagi Y, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Ando K, et al. Among authors: satake h. Int J Clin Oncol. 2017 Oct;22(5):913-920. doi: 10.1007/s10147-017-1140-z. Epub 2017 May 19. Int J Clin Oncol. 2017. PMID: 28526907 Clinical Trial.
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, Satake H, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Sugiyama M, Komatsu Y, Okuyama H, Baba E, Sakai D, Watanabe T, Tamura T, Yamashita K, Gosho M, Shimada Y. Moriwaki T, et al. Among authors: satake h. Oncologist. 2018 Jan;23(1):7-15. doi: 10.1634/theoncologist.2017-0275. Epub 2017 Sep 11. Oncologist. 2018. PMID: 28894015 Free PMC article.
Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, Segawa Y, Nakamura M, Sasaki K, Nagao N, Hatachi Y, Yuasa Y, Asami S, Takeuchi M, Furukawa H, Nakajima T; JACCRO GC-06 Study Group. Kimura Y, et al. Gastric Cancer. 2018 May;21(3):421-427. doi: 10.1007/s10120-017-0766-x. Epub 2017 Sep 21. Gastric Cancer. 2018. PMID: 28936560 Free PMC article. Clinical Trial.
477 results